Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT01303237 Terminated - Clinical trials for Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

PMS LAD SCCHN
Start date: February 28, 2011
Phase: N/A
Study type: Observational

This prospective, observational, multicentre, post marketing surveillance study will collect safety and efficacy information on patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN) treated with Cetuximab and Radiotherapy (RT) based on the locally approved label.

NCT ID: NCT01298960 Terminated - Clinical trials for Complications; Artificial Fertilization, Introduction of Embryo in Embryo Transfer

Growth Hormone (GH) in in Vitro Fertilization (IVF) Poor-responder Patients

FUNDEX001
Start date: February 2011
Phase: Phase 2
Study type: Interventional

Experimental study to evaluate if rGH addition to a standard controlled ovarian stimulation treatment improves ovarian response in women with previous poor ovarian response.

NCT ID: NCT01296854 Terminated - Clinical trials for Pulmonary Disease, Chronic Obstructive

The Effect of Spa Treatment on Chronic Obstructive Pulmonary Disease

BPCeaux
Start date: May 2011
Phase: N/A
Study type: Interventional

The primary objective of this study is to measure and compare the number of exacerbations (moderate or severe) between the two groups of randomized patients with and without thermal treatment). An exacerbation is defined by an increase in symptoms which justifies a unscheduled medical action: increased daily treatment and / or use of corticosteroids, and / or antibiotic therapy. Exacerbations are documented via prescriptions, hospitalisation reports or unscheduled visits.

NCT ID: NCT01296061 Terminated - Clinical trials for Acute Graft Rejection

Kidney Transplant Failure

Start date: August 2011
Phase:
Study type: Observational

Primary Hypotheses: 1. Among patients who retain the failed kidney transplant, those who continue immunosuppressant medication will have more deaths than patients who discontinue these drugs 2. Among patients who retain the failed kidney transplant, those who continue immunosuppressant medication will have more hospitalizations for sepsis than patients who discontinue these drugs 3. Among patients who retain the failed kidney transplant, those who continue immunosuppressant medication will have fewer rejection events than patients who discontinue these drugs Secondary Hypotheses: 1. Patients who undergo elective nephrectomy (to remove the failed kidney transplant) will have fewer deaths than those who retain the failed kidney transplant 2. Patients who undergo elective nephrectomy (to remove the failed kidney transplant) will have fewer hospitalizations for sepsis than those who retain the failed kidney transplant 3. Among patients who retain the failed kidney transplant, those who continue immunosuppressant medication will have lower levels of allosensitization (anti-HLA antibodies) than those who discontinue these drugs 4. Patients who undergo elective nephrectomy will have higher levels of allosensitization (anti-HLA antibodies) than patients who retain the failed kidney transplant

NCT ID: NCT01293500 Terminated - Clinical trials for SIRS (Systemic Inflammatory Response Syndrome(

Goal-directed Resuscitative Interventions During Pediatric Inter-facility Transport (The GRIPIT Trial)

GRIPIT
Start date: October 2010
Phase: N/A
Study type: Interventional

Recent advances in critical care medicine have dramatically improved morbidity and mortality of critical illness. Goal-directed therapy protocols have been instrumental in this change. Goal-directed therapy standardizes the rapid delivery of definitive care in illnesses such as SIRS (Systemic Inflammatory Response Syndrome) and head trauma. Although this treatment approach has been shown to improve clinical outcomes, it has not been widely adopted outside academic medical centers. Further improvement in outcomes of critical illness is likely if goal-directed therapy is utilized early in the course of care. To facilitate this early adoption, goal-directed therapeutic protocols should be developed and implemented by specialized pediatric transport teams. The investigators hypothesize that the institution of goal-directed therapy during pediatric interfacility transport will improve the outcomes of critically ill children. The GRIPIT Trial (Goal-directed Resuscitative Interventions during Pediatric Inter-facility Transport) will compare outcomes of pediatric SIRS patients before and after the implementation of a goal-directed therapeutic protocol during transport. This will be the first test of goal-directed therapy in the transport environment. Data will be collected on pediatric SIRS patients transported by the Angel One Transport Team at Arkansas Children's Hospital before and after protocol implementation. Outcome measures will include length of hospital stay, length of intensive care unit (ICU) stay, incidence of multiple organ dysfunction syndrome (MODS), and required therapeutic interventions during ICU stay (TISS-28 scores). In addition, NIRS (Near-Infrared Spectroscopy) monitoring will be used as a cerebral and somatic oxygenation trend monitor, to determine its effectiveness as a resuscitation guide for pediatric SIRS during transport. NIRS trends are useful as a surrogate marker for systemic venous saturations, known to decrease with severe SIRS.

NCT ID: NCT01291784 Terminated - Myelofibrosis Clinical Trials

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Start date: February 2011
Phase: Phase 1
Study type: Interventional

TGF-β is a cytokine that is found to be upregulated in the bone marrow of patients with myelofibrosis. This cytokine likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. The investigators propose that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation. This is a novel approach to the treatment of patients with myelofibrosis.

NCT ID: NCT01291134 Terminated - Clinical trials for Cervical Degenerative Disc Disease

PureGen: Radiographic Analysis of Fusion for ACDF

Start date: February 2011
Phase:
Study type: Observational

The purpose of this study is to evaluate the rate and quality of spinal fusion utilizing PureGen Osteoprogenitor Cell Allograft in Anterior Cervical Discectomy and Fusion (ACDF).

NCT ID: NCT01289938 Terminated - Clinical trials for Drug Metabolism, Poor, CYP2D6-RELATED

Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine

MalD
Start date: July 2009
Phase: Phase 1
Study type: Interventional

Pharmacokinetic of Metoclopramide (MCP) in correlation to polymorphisms of CYP2D6 and Dopamine-D2-Receptor. Pharmacokinetic of Diphenhydramine (DPH) in correlation to polymorphisms of CYP2D6

NCT ID: NCT01288131 Terminated - Clinical trials for Anti-r-HuEpo Associated PRCA Subjects

Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment

Start date: January 2009
Phase: Phase 3
Study type: Interventional

Recombinant human erythropoietin (r-HuEpo) has been used to treat renal anemia and improve morbidity and mortality in chronic kidney disease. Subcutaneous use of r-HuEpo causes immunogenicity and develops anti-r-HuEpo associated pure red cell aplasia (PRCA). The treatment of anti-r-HuEpo associated pure red cell aplasia is controversial. The investigators aim to evaluate the treatment for anti-r-HuEpo associated pure red cell aplasia in this study.

NCT ID: NCT01287338 Terminated - Clinical trials for Seasonal Allergic Conjunctivitis to Ragweed

A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test if olopatadine punctal plugs can reduce the symptoms (itching) of allergic conjunctivitis to ragweed in an Environmental Exposure Chamber model.